Beyhan Atasevan

发表

Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: Analysis of PAOLA-1/ENGOT-ov25 phase III trial.

K. Yonemori, I. Vergote, I. Ray-Coquard, 2022, Journal of Clinical Oncology.